¼¼°èÀÇ À§¾Ï ½ÃÀå
Gastric Cancer
»óǰÄÚµå : 1731084
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 582 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,056,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,169,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

À§¾Ï ¼¼°è ½ÃÀåÀº 2030³â±îÁö 84¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 33¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â À§¾Ï ¼¼°è ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 16.9%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 84¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¼±¾ÏÀº CAGR 14.8%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 24¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¸²ÇÁÁ¾ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ CAGR·Î 19.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 8¾ï 9,310¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 21.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ À§¾Ï ½ÃÀåÀº 2024³â¿¡ 8¾ï 9,310¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 18¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 21.9%·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 12.8%¿Í 15.1%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 13.4%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ À§¾Ï ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ¼ºÀå ÃËÁø¿äÀÎ Á¤¸®

À§¾Ï Á¶»ç°¡ ¼¼°è º¸°Ç¿¡ ´õ Áß¿äÇÑ ÀÌÀ¯´Â ¹«¾ùÀϱî¿ä?

À§¾ÏÀº ¿©ÀüÈ÷ Àü ¼¼°è ¾Ï °ü·Ã »ç¸ÁÀÇ ÁÖ¿ä ¿øÀÎ Áß ÇϳªÀ̸ç, ƯÈ÷ µ¿¾Æ½Ã¾Æ, Áßµ¿ ¹× µ¿À¯·´, ³²¹Ì ÀϺΠÁö¿ª¿¡¼­´Â ¿©ÀüÈ÷ ÁÖ¿ä »ç¸Á ¿øÀÎ Áß ÇϳªÀÔ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¾Ï¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Á¶±â ¹ß°ß°ú Ä¡·á¹ýÀÌ Å©°Ô ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. À§¾ÏÀº Ä¡·á ¿É¼ÇÀÌ Á¦ÇÑÀûÀÌ°í »ýÁ¸À²ÀÌ ³·Àº ÁøÇà ´Ü°è¿¡¼­ Áø´ÜµÇ´Â °æ¿ì°¡ ¸¹±â ¶§¹®¿¡ ƯÈ÷ ¹®Á¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ ¶§¹®¿¡ ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç, ÷´Ü ¿µ»óÁø´Ü ±â¼ú µî Á¶±â Áø´Ü µµ±¸¿Í ±â¼ú¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖÀ¸¸ç, Áúº´À» Á¶±â¿¡ ¹ß°ßÇÏ´Â °ÍÀÌ Áß¿äÇÏ°Ô ¿©°ÜÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ç¥Àû Ä¡·á¹ýÀ» ã¾Æ³»±â À§ÇØ ÇʼöÀûÀÎ À§¾Ï ¹ßº´ÀÇ ±Ùº»ÀûÀÎ ºÐÀÚ ±âÀüÀ» ±Ô¸íÇÏ´Â °ÍÀÌ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. ƯÈ÷ Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ®±Õ °¨¿°, À¯ÀüÀÚ µ¹¿¬º¯ÀÌ, ½ÄÀÌ ¿äÀÎÀÇ ¿ªÇÒ¿¡ ´ëÇÑ Á¶»ç´Â ÀÌ ÁúȯÀÇ Áß¿äÇÑ À§ÇèÀÎÀÚ·Î È®ÀεǸ鼭 ´õ¿í ź·ÂÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ±× °á°ú, Ä¡·á¹ýÀ» ¹ßÀü½Ã۰í ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϱâ À§ÇØ °ø°ø ¹× ¹Î°£ ÀÇ·á±â°üÀÇ Áö¿øÀ» ¹Þ¾Æ ¿¬±¸¿¡ ´ëÇÑ ÀÚ±ÝÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. À§¾ÏÀ̶ó´Â Áúº´°ú ±× º¹ÀâÇÑ Æ¯¼º¿¡ ´ëÇÑ Àü ¼¼°èÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó °úÇÐÀÚµéÀº ¸é¿ª ¿ä¹ý, Á¤¹Ð ÀÇÇÐ, ¸ÂÃãÇü ¾Ï Ä¡·á¿Í °°Àº »õ·Î¿î Ä¡·á Á¢±Ù¹ýÀ» ¸ð»öÇϰí ÀÖÀ¸¸ç, ÀÌ ¸ðµç °ÍÀÌ À§¾Ï ÅðÄ¡¸¦ À§ÇÑ ±â¼ú Çõ½ÅÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

Ä¡·áÀÇ ¹ßÀüÀº À§¾ÏÀÇ »óȲÀ» ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

À§¾ÏÀÇ Ä¡·á »óȲÀº Áö³­ 10³â°£ Å©°Ô ¹ßÀüÇÏ¿© ¼ö¼ú ±â¼ú°ú Àü½Å ¿ä¹ý ¸ðµÎ ¹ßÀüÇÏ¿© ȯÀڵ鿡°Ô »õ·Î¿î Èñ¸ÁÀ» °¡Á®´ÙÁÖ¾ú½À´Ï´Ù. °ú°Å¿¡´Â ¼ö¼úÀÌ Á¶±â À§¾ÏÀÇ ÁÖ¿ä Ä¡·á¹ýÀ̾úÁö¸¸, Áø´Ü ½Ã ±ÙÄ¡Àû ¼ö¼úÀÌ °¡´ÉÇÑ È¯ÀÚ´Â ±ØÈ÷ ÀϺο¡ ºÒ°úÇß½À´Ï´Ù. ÇÏÁö¸¸ ÃÖ¼Òħ½À¼ö¼úÀÇ µîÀåÀ¸·Î ȯÀÚµéÀº º¸´Ù ´ú ħ½ÀÀûÀÎ ¼ö¼úÀ» ¹ÞÀ» ¼ö ÀÖ°Ô µÇ¾ú°í, ȸº¹¿¡ ¼Ò¿äµÇ´Â ½Ã°£ÀÌ ´ÜÃàµÇ°í ¼ö¼ú ÈÄ ¿¹Èĵµ °³¼±µÇ°í ÀÖ½À´Ï´Ù. ¼ö¼ú°ú ´õºÒ¾î È­Çпä¹ý, ¹æ»ç¼± ¿ä¹ý, Ç¥Àû Ä¡·á´Â ƯÈ÷ ÁøÇ༺ À§¾ÏÀÇ °æ¿ì Ä¡·á ¿ä¹ýÀÇ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. Æ®¶ó½ºÅõÁÖ¸¿(Çã¼Áƾ)°ú °°Àº Ç¥ÀûÄ¡·áÁ¦´Â À§¾ÏÀÇ »ó´ç ºÎºÐÀ» Â÷ÁöÇÏ´Â HER2 ¾ç¼º À§¾Ï Ä¡·á¿¡ È¿°ú°¡ ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÃÖ±Ù¿¡´Â ƯÈ÷ ÁøÇ༺ À§¾Ï ȯÀÚ¿¡°Ô À¯¸ÁÇÑ Ä¡·á¹ýÀ¸·Î ¸é¿ª¿ä¹ýÀÌ µîÀåÇϰí ÀÖ½À´Ï´Ù. Æèºê·Ñ¸®ÁÖ¸¿(ŰƮ·ç´Ù)°ú °°Àº ¸é¿ª°ü¹®¾ïÁ¦Á¦´Â À¯¸ÁÇÑ °á°ú¸¦ º¸¿© ´Ù¸¥ Ä¡·á ¿É¼ÇÀ» ´Ù ½á¹ö¸° ȯÀڵ鿡°Ô »õ·Î¿î ±æÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºÐÀÚ ÇÁ·ÎÆÄÀϸµ°ú À¯ÀüÀÚ °Ë»çÀÇ ¹ßÀüÀ¸·Î °³ÀÎÀÇ Á¾¾ç Ư¼º¿¡ ¸Â´Â ¸ÂÃãÇü Ä¡·á °èȹÀ» ¼ö¸³ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ´õ ¸¹Àº Ä¡·á¹ýÀÌ µîÀåÇÔ¿¡ µû¶ó, ´õ ³ªÀº Ä¡·á °á°ú¸¦ ¾ò±â À§ÇØ ÀÌ·¯ÇÑ Ä¡·á¹ýÀ» °áÇÕÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß°í ÀÖÀ¸¸ç, ÀÌÁß¿ä¹ý, ¸é¿ª¿ä¹ý°ú È­Çпä¹ýÀÇ º´¿ë, ±âŸ ½Ã³ÊÁö È¿°úÀÇ À¯¿ë¼ºÀ» °ËÅäÇÏ´Â ÀÓ»ó½ÃÇèÀÌ È°¹ßÈ÷ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.

À§¾Ï ¹ßº´·ü Áõ°¡ÀÇ ÁÖ¿ä ¿äÀÎÀº?

¼¼°èÀûÀ¸·Î À§¾Ï ¹ßº´·üÀÌ Áõ°¡ÇÏ´Â µ¥¿¡´Â ¿©·¯ °¡Áö ¿äÀÎÀÌ ±â¿©Çϰí ÀÖÀ¸¸ç, »ýȰ½À°ü°ú ȯ°æÀû ¿µÇâÀÌ Áúº´ ¹ßº´¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä À§Çè ¿äÀÎ Áß Çϳª´Â ¸¸¼º ¿°ÁõÀ» À¯¹ßÇϰí À§¾Ï À§ÇèÀ» ³ôÀÌ´Â °ÍÀ¸·Î ¾Ë·ÁÁø Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ®±Õ °¨¿°ÀÔ´Ï´Ù. Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ®±Õ °¨¿°Àº ƯÈ÷ ½ÅÈï±¹¿¡¼­ ¸¹ÀÌ ¹ß»ýÇÏÁö¸¸, À§»ý ȯ°æÀÇ °³¼±°ú Ä¡·á¹ýÀÇ ¹ßÀüÀ¸·Î ¼±Áø±¹¿¡¼­´Â ±× À¯º´·üÀÌ °¨¼ÒÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ½Ä½À°ü Àå¾Ö, Èí¿¬, À½ÁÖ µî ±âŸ »ýȰ½À°ü °ü·Ã ¿äÀÎÀº À§¾Ï ¹ßº´·ü »ó½ÂÀÇ ÁÖ¿ä ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¼¼°è ¿©·¯ Áö¿ª¿¡¼­ ÈçÈ÷ º¼ ¼ö ÀÖ´Â ¿°Àå, ÈÆÁ¦, ÀýÀÓ µîÀÇ ½Ä½À°üÀº À§¾Ï ¹ß»ý À§Çè Áõ°¡¿Í °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºñ¸¸°ú ¿îµ¿ ºÎÁ·Àº ¹ß¾Ï¿¡ ±â¿©ÇÏ´Â ¿°ÁõÀ» Áõ°¡½Ã۰í Àå³» ¼¼±ÕÃÑÀ» º¯È­½ÃŰ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ¾î Áß¿äÇÑ À§Çè ¿äÀÎÀ¸·Î ¶°¿À¸£°í ÀÖ½À´Ï´Ù. À¯ÀüÀû ¼ÒÀεµ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, À¯Àü¼º ¹Ì¸¸¼º ÁõÈıº(HDGC)°ú °°Àº ƯÁ¤ À¯Àü¼º ÁõÈıºÀº °³ÀÎÀ» ´õ ³ôÀº À§Çè¿¡ ³ëÃâ½Ãŵ´Ï´Ù. ¶ÇÇÑ, ³ªÀ̵µ Áß¿äÇÑ ¿ä¼Ò·Î, 50¼¼ À̻󿡼­ À§¾Ï ¹ß»ý À§ÇèÀÌ Å©°Ô Áõ°¡ÇÕ´Ï´Ù. µû¶ó¼­ À§¾Ï ¹ßº´·ü Áõ°¡´Â ȯ°æ, ½Ä½À°ü, À¯Àü, »ýȰ½À°üÀÇ º¹ÇÕÀûÀÎ ¿äÀο¡ ±âÀÎÇϸç, Á¶±â ¹ß°ß°ú ÁøÇà ´Ü°è¿¡¼­ÀÇ È¿°úÀûÀÎ Ä¡·á ´É·ÂÀ̶ó´Â °úÁ¦¿Í ÇÔ²² À§¾ÏÀÇ ¹ßº´·ü Áõ°¡´Â ȯ°æ, ½Ä½À°ü, À¯Àü, »ýȰ½À°üÀÇ º¹ÇÕÀûÀÎ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù.

À§¾Ï Ä¡·á ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀº?

À§¾Ï Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ÀÇÇÐ ¿¬±¸ÀÇ ¹ßÀü, ÀÇ·á ÅõÀÚ Áõ°¡, ÀÏ¹Ý ´ëÁßÀÇ ÀÎ½Ä Áõ°¡ µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. À§¾Ï ¹ßº´·üÀº ƯÈ÷ °í·ÉÈ­ ¹× Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ® °¨¿°·üÀÌ ³ôÀº ±¹°¡¿¡¼­ Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ °³¹ßµµ»ó±¹¿¡¼­ÀÇ ÀÇ·á Á¢±Ù¼º È®´ëµµ Ä¡·á¸¦ ¿øÇϴ ȯÀÚ ¼ö Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. Á¶±â Áø´ÜÀº ¿©ÀüÈ÷ Áß¿äÇÑ °úÁ¦ÀÌÁö¸¸, º¸´Ù Áøº¸µÈ ½ºÅ©¸®´× ¹× Áø´Ü µµ±¸ÀÇ °³¹ß·Î ÀϺΠÁö¿ª¿¡¼­´Â Á¶±â ¹ß°ßÀÌ °¡´ÉÇØÁö°í, Ä¡·á°¡ ´õ È¿°úÀûÀ̸ç, »ýÁ¸À²ÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿Í Á¤¹Ð Á¾¾çÇп¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁø °Íµµ Å« ¿øµ¿·ÂÀ̸ç, °³ÀÎÀÇ À¯ÀüÀû, ºÐÀÚÀû ÇÁ·ÎÆÄÀÏ¿¡ ¸ÂÃá Ä¡·á°¡ °¡´ÉÇØÁ® º¸´Ù È¿°úÀûÀ̰í Ç¥ÀûÈ­µÈ Ä¡·á·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿¿Í ºÐÀÚÁø´ÜÀÇ ÅëÇÕÀ» ÅëÇØ ÀÇ»ç´Â Á¾¾çÀÇ Æ¯Á¤ Ư¼º¿¡ µû¶ó ȯÀÚ¿¡°Ô °¡Àå Å« ÇýÅÃÀ» ÁÙ ¼ö ÀÖ´Â Ä¡·á¹ýÀÌ ¹«¾ùÀÎÁö ÆÄ¾ÇÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ¸é¿ª ¿ä¹ý¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í À§¾Ï¿¡ ´ëÇÑ Àû¿ëÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù. ¾Ï¼¼Æ÷¿Í ½Î¿ì±â À§ÇØ ½ÅüÀÇ ¸é¿ª ü°è¸¦ ÀÌ¿ëÇÏ´Â ¸é¿ª ¿ä¹ýÀº ÁøÇ༺ ¶Ç´Â ÀüÀ̼º À§¾Ï ȯÀÚÀÇ Ä¡·á¿¡ À¯¸ÁÇϸç, ±× °³¹ßÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦¾à¾÷°è°¡ »õ·Î¿î Ä¡·á¹ý ¹× º´¿ë¿ä¹ý °³¹ß¿¡ Á¡Á¡ ´õ ÁýÁßÇϰí ÀÖÀ¸¸ç, À§¾Ï¿¡ ƯȭµÈ ÀÓ»ó½ÃÇèÀÇ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó Áö¼ÓÀûÀÎ ¹ßÀü°ú ȯÀÚ ¿¹ÈÄ °³¼±¿¡ ±â¿©ÇÏ¿© À§¾Ï Ä¡·á ½ÃÀåÀ» ´õ¿í °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

Áúº´ À¯Çü(¼±¾ÏÁ¾, ¸²ÇÁÁ¾, À§Àå°ü ±âÁú Á¾¾ç, Ä«¸£½Ã³ëÀ̵å Á¾¾ç, ±âŸ Áúº´ À¯Çü); Ä¡·á À¯Çü(¸é¿ª ¿ä¹ý, Ç¥Àû Ä¡·á, È­ÇÐ ¿ä¹ý, ¹æ»ç¼± ¿ä¹ý ¹× ¼ö¼ú); ¾à¹° Á¾·ù(PD-1 / PD-L1 ¾ïÁ¦Á¦, HER2 ±æÇ×Á¦, VEGFR2 ±æÇ×Á¦, ±âŸ ¾à¹° Á¾·ù); Åõ¿© °æ·Î(°æ±¸, ÁÖ»ç); À¯Åë ä³Î(Àü¹® ¹× ¼Ò¸Å ¾à±¹, º´¿ø ¾à±¹, ±âŸ À¯Åë ä³Î).

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÁÖ¸ñ 48°³»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÍ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

¹«·á ¾÷µ¥ÀÌÆ® °¢±¹ÀÇ ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ, 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» °í°´´Ôµé²² Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м® :

¹Ì±¹ <>& Áß±¹ <>& ¸ß½ÃÄÚ <>& ij³ª´Ù <>&EU <>& ÀϺ» <>& Àεµ <>& ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Gastric Cancer Market to Reach US$8.4 Billion by 2030

The global market for Gastric Cancer estimated at US$3.3 Billion in the year 2024, is expected to reach US$8.4 Billion by 2030, growing at a CAGR of 16.9% over the analysis period 2024-2030. Adenocarcinoma, one of the segments analyzed in the report, is expected to record a 14.8% CAGR and reach US$2.4 Billion by the end of the analysis period. Growth in the Lymphoma segment is estimated at 19.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$893.1 Million While China is Forecast to Grow at 21.9% CAGR

The Gastric Cancer market in the U.S. is estimated at US$893.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 21.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.8% and 15.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.4% CAGR.

Global Gastric Cancer Market - Key Trends & Drivers Summarized

Why Is Gastric Cancer Research Becoming More Critical for Global Health?

Gastric cancer remains one of the leading causes of cancer-related deaths worldwide, particularly in regions such as East Asia, Central and Eastern Europe, and parts of South America. The increasing recognition of its global health burden has spurred significant advancements in both early detection and treatment options. Gastric cancer is particularly challenging because it is often diagnosed at an advanced stage when treatment options are limited, and survival rates are low. This has led to a growing focus on early diagnostic tools and technologies, such as biomarker testing and advanced imaging techniques, to identify the disease at its earliest stages. Furthermore, there is an increasing emphasis on understanding the molecular mechanisms underlying gastric cancer development, which is crucial for identifying targeted therapies. In particular, research into the role of Helicobacter pylori infection, genetic mutations, and dietary factors has gained momentum, as these are identified as key risk factors for the disease. As a result, funding for gastric cancer research has risen, supported by both public and private health organizations, to advance treatment methods and improve patient outcomes. With the rise in global awareness of the disease and its complex nature, scientists are exploring new therapeutic approaches such as immunotherapy, precision medicine, and personalized cancer treatments, all of which are driving innovations in the fight against gastric cancer.

How Are Advances in Treatment Shaping the Gastric Cancer Landscape?

The treatment landscape for gastric cancer has evolved significantly over the past decade, with advancements in both surgical techniques and systemic therapies offering new hope for patients. In the past, surgery was the main treatment option for early-stage gastric cancer, but only a small percentage of patients were candidates for curative surgery at the time of diagnosis. However, with the advent of minimally invasive procedures, patients are now able to undergo less invasive surgeries, which reduce recovery times and improve post-operative outcomes. In addition to surgery, chemotherapy, radiation therapy, and targeted therapies have become essential components of the treatment regimen, particularly for advanced stages of gastric cancer. Targeted therapies, such as trastuzumab (Herceptin), have shown efficacy in treating HER2-positive gastric cancers, which make up a significant proportion of gastric cancer cases. More recently, immunotherapy has emerged as a promising treatment option, particularly for patients with advanced gastric cancer. Immune checkpoint inhibitors such as pembrolizumab (Keytruda) have demonstrated encouraging results, offering new avenues for patients who have exhausted other treatment options. Moreover, advancements in molecular profiling and genetic testing are allowing for more personalized treatment plans tailored to an individual’s specific tumor characteristics. As more therapies become available, there is an increased focus on combining these modalities for better outcomes, with clinical trials actively investigating the benefits of dual therapies, immunotherapy combined with chemotherapy, and other synergistic approaches to treating gastric cancer.

What Are the Key Factors Contributing to the Increasing Incidence of Gastric Cancer?

Several factors are contributing to the increasing global incidence of gastric cancer, with lifestyle and environmental influences playing a significant role in disease development. One of the major risk factors is infection with Helicobacter pylori, a bacterium that is known to cause chronic inflammation and increase the risk of gastric cancer. H. pylori infection is particularly prevalent in developing countries, but with better sanitation and medical treatments, its prevalence is decreasing in developed nations. However, other lifestyle-related factors, such as poor diet, smoking, and alcohol consumption, continue to be major contributors to the rising incidence of gastric cancer. Diets rich in salted, smoked, or pickled foods, which are common in many parts of the world, have been linked to an increased risk of gastric cancer. Additionally, obesity and lack of physical activity are emerging as significant risk factors, as they are known to increase inflammation and alter gut microbiota, both of which contribute to carcinogenesis. Genetic predisposition also plays a role, with certain inherited syndromes, such as hereditary diffuse gastric cancer (HDGC), putting individuals at higher risk. Additionally, age is a significant factor, with the risk of developing gastric cancer increasing significantly in individuals over 50. The rise in the incidence of gastric cancer can therefore be attributed to a combination of environmental, dietary, genetic, and lifestyle factors, along with the challenges of early detection and the ability to effectively treat the disease in its advanced stages.

What Are the Key Drivers Behind the Growth of the Gastric Cancer Treatment Market?

The growth of the gastric cancer treatment market is driven by several key factors, including advancements in medical research, increasing healthcare investments, and rising public awareness. As the incidence of gastric cancer continues to rise, particularly in countries with aging populations or high rates of Helicobacter pylori infection, the demand for effective treatments is accelerating. The expansion of healthcare access, especially in developing countries, is also contributing to a larger patient population seeking treatment. Early diagnosis remains a significant challenge, but the development of more advanced screening and diagnostic tools has led to earlier detection in some regions, making treatment more effective and improving survival rates. The increasing focus on personalized medicine and precision oncology is another major driver, as treatments are becoming more tailored to an individual’s genetic and molecular profile, leading to more effective and targeted therapies. The integration of biomarkers and molecular diagnostics is enabling physicians to identify which treatments are most likely to benefit patients based on their tumor’s specific characteristics. Additionally, the growing interest in immunotherapy and its application to gastric cancer is another key factor propelling market growth. Immunotherapies, which harness the body’s immune system to fight cancer cells, are showing promise in treating patients with advanced or metastatic gastric cancer, and their development is accelerating the growth of the market. Furthermore, the pharmaceutical industry’s increasing focus on developing novel therapies and combination treatment regimens, as well as the rising number of clinical trials dedicated to gastric cancer, is expected to contribute to continued advancements and better patient outcomes, further driving the gastric cancer treatment market.

SCOPE OF STUDY:

The report analyzes the Gastric Cancer market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Disease Types); Treatment Type (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy & Surgery); Drug Class (PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Other Drug Classes); Administration Route (Oral, Injectable); Distribution Channel (Specialty & Retail Pharmacies, Hospital Pharmacies, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â